Information Provided By:
Fly News Breaks for February 24, 2020
BMRN, FIXX
Feb 24, 2020 | 06:39 EDT
Chardan analyst Geulah Livshits initiated coverage of Homology Medicines (FIXX) with a Buy rating and $34 price target. In a research note to investors, the analyst says that while HMI-102 faces competition from assets in development by BioMarin (BMRN) and others, she believes Homology's potentially-registrational trial design and internal manufacturing capabilities position the company to move quickly. Homology is well positioned to advance its internal programs, Livshits says, adding that the company does not need gene editing to work in order to see upside.
News For FIXX;BMRN From the Last 2 Days
FIXX
Mar 27, 2024 | 08:31 EDT
New option listings for March 27th include KURV YIELD PREMIUM STRATEGY APPLE AAPL ETF (AAPY), YIELDMAX AI OPTION INCOME STRATEGY ETF (AIYY), GRANITESHARES 1X SHORT AMD DAILY ETF (AMDS), KURV YIELD PREMIUM STRATEGY AMAZON AMZN ETF (AMZP), KURV YIELD PREMIUM STRATEGY GOOGLE GOOGL ETF (GOOP), Hamilton Insurance Group Ltd (HG), KURV YIELD PREMIUM STRATEGY MICROSOFT MSFT ETF (MSFY), YIELDMAX MSTR OPTION INCOME STRATEGY ETF (MSTY), KURV YIELD PREMIUM STRATEGY NETFLIX NFLX ETF (NFLP), Net Lease Office Properties (NLOP), KURV YIELD PREMIUM STRATEGY TESLA TSLA ETF (TSLP), YIELDMAX ULTRA OPTION INCOME STRATEGY ETF (ULTY), YIELDMAX MAGNIFICENT 7 FUND OF OPTION INCOME ETFS (YMAG), and YIELDMAX UNIVERSE FUND OF OPTION INCOME ETFS (YMAX). Option delistings effective March 27th include Fisker Inc. (FSR), Homology Medicines Inc (FIXX), DIGITAL WORLD ACQUISITION CORP (DWAC), and Curo Group Holdings Corp (CURO).